Metagenomi Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Metagenomi Therapeutics, Inc. (formerly Metagenomi, Inc.) is an early-stage, clinical-intent biotechnology company focused on discovering and developing proprietary gene-editing systems derived from microbial genomes (metagenomics). The company leverages its extensive database of natural microbial genomes to identify novel, compact CRISPR-like nucleases and other gene-editing tools. Its lead wholly-owned program is MGX-001, a gene-integration therapy targeting Hemophilia A. Additionally, Metagenomi maintains a strategic collaboration with Ionis Pharmaceuticals to develop therapies for cardiometabolic indications.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In late 2025, Metagenomi implemented a strategic reorientation to focus resources on its lead therapeutic program, MGX-001, and its most advanced preclinical assets. This initiative included a 25% workforce reduction and a transition in leadership, with Jian Irish succeeding Brian Thomas as CEO.
Expected impact: Extends the company's cash runway into the fourth quarter of 2027, allowing it to reach key clinical data readouts for MGX-001.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Leverages Ionis' expertise in RNA-targeted therapeutics and Metagenomi's next-generation gene-editing systems to pursue validated and novel genetic targets, primarily in cardiometabolic diseases [1.1.5].
Terms: $80 million upfront payment received by Metagenomi in November 2022, with potential for future milestone payments and royalties. The deal has a total potential value of nearly $3 billion across eight targets.
Out-licensing of Metagenomi's gene-editing technology for ex vivo cell therapy applications, specifically supporting Affini-T's T-cell receptor-based therapies.
Terms: Metagenomi received 933,650 shares of Affini-T common stock upon achieving a development milestone in 2024. Affini-T exercised an option for a non-exclusive license in April 2025.